- Trial phase
- Approved (EU), Phase 3 ongoing globally
- Time to market
- Approved in EU (Aug 2024) and launching commercially; US timeline unknown after two CRLs
- Why 4/10
- Ordspono is already approved and launching in the EU (since Aug 2024) with no pending US FDA catalyst. Two CRLs were issued (most recently Aug 2025, on manufacturing site issues) and no third resubmission has been announced. The next potential triggers are ongoing Phase 3 Olympia readouts, but none have a firm dated binary within ~12 months. Even if successful, Ordspono is a small program within Regeneron's diversified portfolio (Dupixent alone >$17B/yr).
For REGN investors, Ordspono is a non-binary minor commercial asset. The EU launch is underway but sales are small relative to Regeneron's scale. The US path is unclear after two FDA rejections (enrollment timelines, then manufacturing). Watch for: (1) any announcement of a third BLA resubmission, (2) Olympia-3 Part 1B data at ASCO/ASH, and (3) whether EU conditional marketing renewal faces any hurdles.
Price Chart
Executive Summary
Ordspono (odronextamab) is Regeneron's first approved bispecific antibody, cleared in the EU in August 2024 for two types of relapsed/refractory B-cell lymphoma (FL and DLBCL) after prior therapies. It works by bridging cancer cells to immune T-cells. The US path has been rocky, the FDA has rejected it twice (first on confirmatory trial enrollment, then on a third-party manufacturer site inspection). Phase 3 Olympia studies are ongoing globally, with early data in first-line DLBCL looking promising. For Regeneron (a ~$65B market cap biotech with blockbuster Dupixent), Ordspono is a modest commercial contributor, not a needle-mover. GlobalData projects ~$569M peak sales by 2030.
How It Works
Ordspono is a bispecific antibody, a Y-shaped protein engineered to grab two things at once. One arm latches onto CD20, a protein found on the surface of cancerous B-cells (a type of white blood cell). The other arm grabs CD3, found on the patient's own T-cells ("killer" immune cells). By bridging the cancer cell to the T-cell, it tricks the immune system into attacking and destroying the lymphoma.
Trial Status
Approved in the EU since Aug 2024 for relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) after 2+ prior lines. Phase 3 Olympia program is actively enrolling/testing across multiple studies: Olympia-1/2/5 in FL, Olympia-3 in first-line DLBCL (combo with CHOP). Olympia-3 Part 1B results presented at ASCO 2026 showed promising efficacy. A Phase 2 ELM-2 study is active but no longer recruiting (est. primary completion Jul 2026). In the US, the FDA has issued two CRLs, first in Mar 2024 (confirmatory trial enrollment), second in Aug 2025 (Catalent manufacturing site inspection), with no announced resubmission plan.
The Two-Sided Case
Upcoming Catalysts
- Olympia-3 Part 1B randomized data readout (Phase 3 frontline DLBCL), further presentations likely at ASH 2026
- Olympia-1 and Olympia-2 Phase 3 enrollment completion updates for r/r FL
- Any announcement of a third US FDA BLA resubmission and timeline
- EU conditional marketing authorization annual renewal process
- Commercial launch revenue updates in Regeneron quarterly earnings calls
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report